Stoke Therapeutics (NASDAQ:STOK) Trading 1.6% Higher – Should You Buy?

Stoke Therapeutics, Inc. (NASDAQ:STOK) traded up 1.6% during trading on Friday . The company traded as high as $30.52 and last traded at $29.82. 478,898 shares traded hands during trading, a decline of 9% from the average session volume of 526,191 shares. The stock had previously closed at $29.36.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Wedbush lifted their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Canaccord Genuity Group upped their price target on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Needham & Company LLC upped their price target on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Finally, Wolfe Research started coverage on shares of Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Stoke Therapeutics Stock Up 1.6%

The firm’s 50 day simple moving average is $32.24 and its 200-day simple moving average is $32.36. The company has a market capitalization of $1.86 billion, a PE ratio of -10.61 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The company had revenue of $6.23 million during the quarter, compared to the consensus estimate of $6.48 million. As a group, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 EPS for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares in the company, valued at $1,064,979.08. The trade was a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Thomas Leggett sold 2,382 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $74,651.88. Following the sale, the chief financial officer owned 10,172 shares of the company’s stock, valued at approximately $318,790.48. This represents a 18.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 33,291 shares of company stock valued at $1,064,065 in the last ninety days. Corporate insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently bought and sold shares of STOK. Principal Financial Group Inc. purchased a new position in shares of Stoke Therapeutics in the third quarter valued at $1,062,000. Vanguard Group Inc. boosted its stake in shares of Stoke Therapeutics by 7.4% in the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after purchasing an additional 217,616 shares during the period. Baillie Gifford & Co. bought a new position in Stoke Therapeutics during the 4th quarter valued at $7,837,000. Hussman Strategic Advisors Inc. bought a new position in Stoke Therapeutics during the 4th quarter valued at $2,000,000. Finally, Checkpoint Capital L.P. bought a new position in Stoke Therapeutics during the 3rd quarter valued at $4,983,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.